Trial · NCT03805932
Adverse events204
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 204
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 0 | 3 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 1 | 15 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 0 | 3 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 2 | 15 | 4 |
| other | Alanine aminotransferase increased | Investigations | Moxetumomab - Dose Escalation 30 mcg/kg | 1 | 3 | 5 |
| other | Alanine aminotransferase increased | Investigations | Moxetumomab - Dose Expansion 40 mcg/kg | 10 | 15 | 24 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 1 | 3 | 1 |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 1 | 15 | 1 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 0 | 3 | 0 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 1 | 15 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 1 | 3 | 2 |
| other | Anemia | Blood and lymphatic system disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 9 | 15 | 25 |
| other | Anxiety | Psychiatric disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 0 | 3 | 0 |
| other | Anxiety | Psychiatric disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 2 | 15 | 2 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 0 | 3 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 2 | 15 | 4 |
| other | Aspartate aminotransferase increased | Investigations | Moxetumomab - Dose Escalation 30 mcg/kg | 1 | 3 | 4 |
| other | Aspartate aminotransferase increased | Investigations | Moxetumomab - Dose Expansion 40 mcg/kg | 13 | 15 | 40 |
| other | Atrial fibrillation | Cardiac disorders | Moxetumomab - Dose Escalation 30 mcg/kg | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Moxetumomab - Dose Expansion 40 mcg/kg | 1 | 15 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03805932/events